ABAX Abaxis, Inc. (delisted)

Abaxis Announces Launch of a New Hematology System for the Veterinary Market UNION CITY, Calif., May 17 /PRNewswire-FirstCall/ -- Abaxis, Inc. , a medical products company manufacturing point-of-care blood analysis systems, announced today the release and launch of its new VetScan HMII Hematology System (HMII) for the veterinary market. The HMII offers the veterinary professional a next generation hematology instrument with evolutionary advancements in operational simplicity, increased accuracy and precision, expanded database capability, along with enhanced self-cleaning mechanisms for ease of maintenance in the busy veterinary practice. Manufactured by Diatron Messtechnik GmbH exclusively for Abaxis, the HMII is a state of the art hematology instrument offering an 18-parameter CBC (complete blood count) analysis, including a 3-part WBC (white blood cell) differential for the diagnostic assessment of patients by the veterinarian in their clinic. "Providing our customers state of the art medical technology and compact instrument designs are what we strive for at Abaxis," states Clint Severson, Chairman and CEO. "Our new hematology instrument is more in line with our VetScan Chemistry system when it comes to operator simplicity, low maintenance and dependable results for rapid and improved patient diagnosis." Abaxis will continue to support and service its current population of VetScan HMT Hematology customers. ABAXIS develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram, portable analyzer and a series of 8-cm diameter single-use plastic disks, called rotors or reagent discs that contain all the reagents necessary to perform a fixed menu of tests. The system can be operated with minimal training and perform multiple tests on whole blood, serum or plasma samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory. This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. ABAXIS claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in ABAXIS' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. ABAXIS does not undertake and specifically disclaims any obligation to update any forward-looking statements. DATASOURCE: Abaxis, Inc. CONTACT: Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or Retail: Joe Dorame, or Institutional/Analysts: Joe Diaz, both of RCG Capital Markets Group, +1-480-675-0400, for Abaxis, Inc. Web site: http://www.abaxis.com/

Copyright